Nuvation Bio Inc. (NUVB): Shareholders' Equity
$305.72M
As of 2025-12-31
$253.86M
As of 2026-06-30
-22.4%
3-year compound annual growth
+7.3%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $305.72M | -34.1% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $463.79M | -23.4% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $605.12M | -7.6% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $655.08M | -12.2% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $746.00M | +246.8% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $215.08M | n/a | 2022-02-28, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $305.72M | -34.1% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $49.87M | +119.3% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $346.18M | +73.5% |
| Journey Medical Corp (DERM) | 2025-12-31 | $31.85M | +58.7% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $64.72M | -49.8% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $59.02M | +28.0% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $174.13M | -57.9% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $35.27M | +86.0% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $36.98M | +13.5% |
Compare NUVB, FBIO, TNGX, DERM side by side · Screen every company in Pharmaceutical Preparations ↗